Diagnostic performance of MRI-guided vacuum-assisted breast biopsy (VABB): an essential but still underused technique.

IF 3 3区 医学 Q2 ONCOLOGY Breast Cancer Research and Treatment Pub Date : 2025-04-01 Epub Date: 2024-12-18 DOI:10.1007/s10549-024-07579-1
Laura Suman, Elisa D'Ascoli, Catherine Depretto, Alessandro Berenghi, Claudia De Berardinis, Gianmarco Della Pepa, Giovanni Irmici, Daniela Ballerini, Alice Bonanomi, Eleonora Ancona, Gianfranco Paride Scaperrotta
{"title":"Diagnostic performance of MRI-guided vacuum-assisted breast biopsy (VABB): an essential but still underused technique.","authors":"Laura Suman, Elisa D'Ascoli, Catherine Depretto, Alessandro Berenghi, Claudia De Berardinis, Gianmarco Della Pepa, Giovanni Irmici, Daniela Ballerini, Alice Bonanomi, Eleonora Ancona, Gianfranco Paride Scaperrotta","doi":"10.1007/s10549-024-07579-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Magnetic resonance imaging (MRI)-guided vacuum-assisted breast biopsy (VABB) is an increasingly requested procedure, but it implies training and experience both in its execution and in determining radiological-pathological concordance and is therefore performed in dedicated breast centers. The purpose of this study is to evaluate the diagnostic performance of MRI-guided vacuum-assisted biopsy and to determine the upgrade rate after surgery or follow-up.</p><p><strong>Methods: </strong>We retrospectively evaluated all consecutive patients with suspicious MRI findings without corresponding mammographic and ultrasonographic findings who underwent MRI-guided vacuum-assisted breast biopsy (VABB) at our Institution from November 2020 to March 2023. We determined the sensitivity (SE), specificity (SP), positive predictive value (PPV), negative predictive value (NPV) and accuracy of the procedure; we also assessed upgrade rate to malignancies using surgery or at least 1-year negative follow-up as reference standard. Fisher's exact test was used to evaluate the correlation between enhancement size and type (mass/non-mass) and histological outcomes.</p><p><strong>Results: </strong>A total of 121 patients with 122 suspicious breast lesions have been included. 29.5% (n = 36) of these lesions were classified as malignant (B5), 23% (n = 28) were lesions with uncertain malignant potential (B3 lesions), and 47.5% (n =58) were benign (B2). Among B5 lesions, 47.22% (n =17) were ductal carcinomas in situ (DCIS) and 52.77% (n = 19) were invasive carcinomas. Among patients with already diagnosed breast cancer (n = 36), MRI-guided VABB identified additional foci of disease in 36.1% (n = 13) of the cases, specifically 10 foci on the same breast and 3 in the contralateral breast. Accuracy of MRI-guided VABB was 96.7%, SE was 90%, SP was 100%, PPV was 100%, and NPV was 95.3%. 4 benign lesions (B2 and B3) were upgraded to B5 lesions after surgery or follow-up; the upgrade rate to malignancies was 3.28%. Fisher's exact test showed a significant association between enhancement size and histological outcomes (OR = 2.38, p = 0.046), while enhancement type was not significantly correlated (OR = 0.88, p = 0.841). No major complications have been reported.</p><p><strong>Conclusions: </strong>MRI-guided VABB has proven to be a mini-invasive, safe, and accurate procedure for the diagnostic work-up of suspected breast lesions, which can help in the management of patients aiding in the correct surgical decisional process.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"417-423"},"PeriodicalIF":3.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10549-024-07579-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Magnetic resonance imaging (MRI)-guided vacuum-assisted breast biopsy (VABB) is an increasingly requested procedure, but it implies training and experience both in its execution and in determining radiological-pathological concordance and is therefore performed in dedicated breast centers. The purpose of this study is to evaluate the diagnostic performance of MRI-guided vacuum-assisted biopsy and to determine the upgrade rate after surgery or follow-up.

Methods: We retrospectively evaluated all consecutive patients with suspicious MRI findings without corresponding mammographic and ultrasonographic findings who underwent MRI-guided vacuum-assisted breast biopsy (VABB) at our Institution from November 2020 to March 2023. We determined the sensitivity (SE), specificity (SP), positive predictive value (PPV), negative predictive value (NPV) and accuracy of the procedure; we also assessed upgrade rate to malignancies using surgery or at least 1-year negative follow-up as reference standard. Fisher's exact test was used to evaluate the correlation between enhancement size and type (mass/non-mass) and histological outcomes.

Results: A total of 121 patients with 122 suspicious breast lesions have been included. 29.5% (n = 36) of these lesions were classified as malignant (B5), 23% (n = 28) were lesions with uncertain malignant potential (B3 lesions), and 47.5% (n =58) were benign (B2). Among B5 lesions, 47.22% (n =17) were ductal carcinomas in situ (DCIS) and 52.77% (n = 19) were invasive carcinomas. Among patients with already diagnosed breast cancer (n = 36), MRI-guided VABB identified additional foci of disease in 36.1% (n = 13) of the cases, specifically 10 foci on the same breast and 3 in the contralateral breast. Accuracy of MRI-guided VABB was 96.7%, SE was 90%, SP was 100%, PPV was 100%, and NPV was 95.3%. 4 benign lesions (B2 and B3) were upgraded to B5 lesions after surgery or follow-up; the upgrade rate to malignancies was 3.28%. Fisher's exact test showed a significant association between enhancement size and histological outcomes (OR = 2.38, p = 0.046), while enhancement type was not significantly correlated (OR = 0.88, p = 0.841). No major complications have been reported.

Conclusions: MRI-guided VABB has proven to be a mini-invasive, safe, and accurate procedure for the diagnostic work-up of suspected breast lesions, which can help in the management of patients aiding in the correct surgical decisional process.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
mri引导下真空辅助乳腺活检(VABB)的诊断性能:一项必要但仍未充分利用的技术。
背景:磁共振成像(MRI)引导的真空辅助乳腺活检(VABB)是一种越来越被要求的手术,但它需要在其执行和确定放射病理一致性方面的培训和经验,因此在专门的乳腺中心进行。本研究的目的是评估mri引导下的真空辅助活检的诊断性能,并确定手术后或随访后的升级率。方法:我们回顾性评估了2020年11月至2023年3月在我院接受MRI引导下真空辅助乳腺活检(VABB)的所有连续患者,这些患者有可疑的MRI表现,但没有相应的乳房x线和超声检查结果。测定该方法的敏感性(SE)、特异性(SP)、阳性预测值(PPV)、阴性预测值(NPV)和准确性;我们还以手术或至少1年阴性随访作为参考标准评估恶性肿瘤的升级率。使用Fisher精确检验来评估增强大小与类型(肿块/非肿块)和组织学结果之间的相关性。结果:共纳入121例可疑乳腺病变122例。其中29.5% (n = 36)为恶性(B5), 23% (n = 28)为恶性不确定的病变(B3), 47.5% (n =58)为良性(B2)。B5病变中,导管原位癌(DCIS)占47.22% (n =17),浸润性癌占52.77% (n = 19)。在已经诊断为乳腺癌的患者(n = 36)中,mri引导下的VABB在36.1% (n = 13)的病例中发现了额外的疾病灶,其中10个灶在同侧乳房,3个灶在对侧乳房。mri引导下VABB的准确率为96.7%,SE为90%,SP为100%,PPV为100%,NPV为95.3%。4例良性病变(B2、B3)术后或随访后升级为B5病变;恶性升级率为3.28%。Fisher精确检验显示增强大小与组织学结果有显著相关性(OR = 2.38, p = 0.046),而增强类型与组织学结果无显著相关性(OR = 0.88, p = 0.841)。没有重大并发症的报道。结论:mri引导下的VABB已被证明是一种微创、安全、准确的方法,可用于可疑乳腺病变的诊断检查,有助于患者的管理,有助于正确的手术决策过程。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
相关文献
Superconducting Radio-Frequency Cavities
IF 12.4 2区 物理与天体物理Annual Review of Nuclear and Particle SciencePub Date : 2014-10-20 DOI: 10.1146/ANNUREV-NUCL-102313-025612
H. Padamsee
Magneto-thermal limitations in superconducting cavities at high radio-frequency fields
IF 0 Frontiers in electronic materialsPub Date : 2024-03-08 DOI: 10.3389/femat.2024.1339293
I. Parajuli, G. Ciovati, A. Gurevich
来源期刊
CiteScore
6.80
自引率
2.60%
发文量
342
审稿时长
1 months
期刊介绍: Breast Cancer Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in breast cancer a single forum for communication. The journal creates a "market place" for breast cancer topics which cuts across all the usual lines of disciplines, providing a site for presenting pertinent investigations, and for discussing critical questions relevant to the entire field. It seeks to develop a new focus and new perspectives for all those concerned with breast cancer.
期刊最新文献
Correction: Preferences of patients with high-risk HR+/HER2- breast cancer for adjuvant endocrine treatment: an adaptive choice-based conjoint analysis study from Germany. Did the COVID-19 consortium recommendations impact the treatment of breast cancer during the COVID-19 pandemic? Unveiling the role of PANoptosis-related genes in breast cancer: an integrated study by multi-omics analysis and machine learning algorithms. Triaging mammography with artificial intelligence: an implementation study. Diet quality and cardiometabolic health in breast cancer survivors: the Pathways Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1